Ardelyx Bowel Drug Could Rival Actavis’ Linzess

By | October 1, 2014

Scalper1 News

Newly public biotech Ardelyx (ARDX) reported positive midstage trial data for its bowel-disease drug Wednesday, sending Ardelyx stock up 30.9% to 18.60 in early afternoon trading trading on the stock market today. It made its IPO in June at 14. Ardelyx said that tenapanor, which it’s developing in partnership with AstraZeneca (AZN), met its primary endpoint in a study of 371 sufferers from irritable bowel syndrome with constipation (IBS-C). After Scalper1 News

Scalper1 News